Ascendis Pharma A (ASND) Cash & Current Investments (2012 - 2026)

Ascendis Pharma A has reported Cash & Current Investments for 15 years, with the latest figure at $670.6 million in Q1 2026.

• Quarterly Cash & Current Investments fell 42.27% year-over-year to $670.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $670.6 million (down 42.27% YoY) and the FY2025 annual result came in at $717.1 million, down 47.86% from the prior year.
• Cash & Current Investments eased to $670.6 million in Q1 2026 per ASND's latest filing, from $717.1 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $2.0 billion in Q1 2022 and troughed at $429.3 million in Q2 2023.
• A 5-year average of $970.5 million and a median of $743.4 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments surged 274.94% in 2022, then slumped 75.37% in 2023.
• Over 5 years, Cash & Current Investments stood at $471.1 million in 2022, then soared by 89.4% to $892.2 million in 2023, then soared by 54.14% to $1.4 billion in 2024, then sank by 47.86% to $717.1 million in 2025, then dropped by 6.48% to $670.6 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $670.6 million, $717.1 million, and $1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.